Sarepta Therapeutics Inc Investor Call Transcript
Good morning and welcome to Sarrepta's preliminary data readout of its phase 12 studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, Sarreta's Chief Executive Officer. Please go ahead.
Thank you, Shannon. Good morning everyone and thank you for joining our first readout of our clinical data from our programs for FSHD and DM1.
In a moment, you will hear from our President of R&D and technical operations, Doctor Luis Redio Clayakach, our Chief Medical Officer, Doctor James Richardson, and during our Q&A session, our President and Chief Operating Officer, Ian Estepan, and importantly, our Chief Scientific Officer, Doctor Rachel Potter. But before that, let me make a very, a few very short introductory remarks.
Now, first, I must remind you that we will be making forward-looking statements today, so please refer to our various public filings.
For the risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
